<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191450</url>
  </required_header>
  <id_info>
    <org_study_id>EF 114</org_study_id>
    <nct_id>NCT01191450</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension</brief_title>
  <acronym>CARD</acronym>
  <official_title>A Study to Evaluate the Safety and Efficacy of Chlorthalidone in Combination With Amiloride as a Treatment for Elderly Patients With Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Chlorthalidone 25 mg +
      amiloride hydrochloride 5 mg association in the treatment of elderly patients with arterial
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the efficacy and safety of the association of Chlorthalidone 25 mg + amiloride
      hydrochloride 5 mg (Diupress® Eurofarma) in the treatment of elderly patients with arterial
      hypertension, compared to Chlorthalidone 25mg (Higroton® Laboratório Novartis) in same
      presentation form.

      Some eligibility criteria:

      perform blood and urine tests; ECG (electrocardiogram); ABPM (Ambulatory Blood Pressure
      Monitoring; Echocardiogram;Doppler Echocardiogram
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Potassium level</measure>
    <time_frame>After starting the medication</time_frame>
    <description>Potassium level &lt;4.0 mEq/L after starting the medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Will be considered as secondary outcomes BP &lt;140 X 90 mmHg after 12 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Higroton®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorthalidone 25mg - one oral tablet a day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diupress®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone 25 mg + amiloride hydrochloride 5 mg</intervention_name>
    <description>Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks</description>
    <arm_group_label>Diupress®</arm_group_label>
    <other_name>Diupress® (Eurofarma Laboratórios Ltda.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higroton® Laboratório Novartis</intervention_name>
    <description>Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks</description>
    <arm_group_label>Higroton®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systolic blood pressure between 140 mmHg - 159 mmHg

          -  Diastolic blood pressure between 90 mmHg - 99 mmHg

          -  Subject aged ≥ 60 years old

          -  Be able to comply with instructions, attend study follow-up visits and be willing to
             participate in the research project.

          -  Diagnosis of stage 1 arterial hypertension with no prior treatment more than 120 days
             or uncontrolled during antihypertensive agent administration.

        Exclusion Criteria:

          -  Any serious or severe clinically significant medical condition.

          -  Psychiatric or neurological diseases

          -  A condition that, as per Principal Investigator's opinion, may interfere with the
             optimal participation in the study, or that may result in special risk to the patient.

          -  Participation in any other investigational study within 12 months prior to Visit 1.

          -  Known medical history of allergy, hypersensitivity or intolerance to any of the
             formulation compounds to be used in this study

          -  Routine prior use of diuretics

          -  Oral anticoagulant use

          -  Fast glycemia &gt; 150 mg/dL

          -  Medical treatment, not related to study, scheduled for the clinical trial duration;
             except non-serious, controlled comorbidities in current medical follow-up.

          -  Expected onset of additional antihypertensive drug after the study onset

          -  Acute myocardial infarction within last 6 months

          -  Prior decompensated coronary artery disease

          -  Known thyroid, renal or liver dysfunction, at investigator's discretion

          -  Obesity - body mass index (BMI) &gt; 33 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Guilherme O Silva</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Marcelina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Humberto Freitas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital São Camilo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Carlos A Ayob</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Pesquisas Clínicas do Instituto de Moléstias Cardiovasculares</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Jorge S Franco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade de Pesquisa Clínica (UPECLIN)- Hospital das Clínicas UNESP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Augusto A Costa</last_name>
    <role>Principal Investigator</role>
    <affiliation>FGM - Clínica Paulista de Doenças Cardiovasculares</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriana C Forti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Estudos de Diabetes e Hipertensão</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paulo Cesar V Jardim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liga de Hipertensão Arterial - Universidade Federal de Goiás</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marise L Castro</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMA - Instituto de Medicina Avançada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela G Barbieri</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDOES - Centro de Diagnóstico e Pesquisa de Osteoporose do Espírito Santo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fábio José C Fucci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Moléstias Cardiovasculares de Tatuí</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Estela B Pannuti</last_name>
    <phone>55 11 4144-9680</phone>
    <email>estela.pannuti@eurofarma.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Estudos de Diabetes e Hipertensão</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviana</last_name>
      <phone>55 85 3105-8300</phone>
      <email>cedh@cedh.med.br</email>
    </contact>
    <investigator>
      <last_name>Adriana C Forti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEDOES - Centro de Diagnóstico e Pesquisa de Osteoporose do Espírito Santo</name>
      <address>
        <city>Vitória</city>
        <state>Espirito Santo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Carolina</last_name>
      <phone>55 27 21250220</phone>
      <email>pesquisa2@cedoes.com.br</email>
    </contact>
    <investigator>
      <last_name>Daniela G Barbieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liga de Hipertensão Arterial - Universidade Federal de Goiás</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Paula Souza</last_name>
      <phone>55 62 3269-8433</phone>
      <email>anapauladesouza@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Paulo Cesar V Jardim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina - UNESP</name>
      <address>
        <city>Botucatu</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mônica</last_name>
      <phone>55 14 3811-6574</phone>
      <email>mapaula@fmb.unesp.br</email>
    </contact>
    <investigator>
      <last_name>Roberto Jorge S Franco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do IMC - Instituto de Moléstias Cardiovasculares</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clotilde</last_name>
      <phone>55 17 3203-4051</phone>
      <email>dcimc@imconline.com.br</email>
    </contact>
    <investigator>
      <last_name>José Carlos A Ayoub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Moléstias Cardiovasculares de Tatuí</name>
      <address>
        <city>Tatuí</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Frare</last_name>
      <phone>55 15 3305 1260</phone>
      <email>lucasfrare@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Fábio José C Fucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Paulista de Doenças Cardiovasculares - FGM</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel</last_name>
      <phone>55 11 3373-7310</phone>
    </contact>
    <investigator>
      <last_name>Fernando Augusto A Costa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel</last_name>
      <phone>55 11 2217-3766</phone>
      <email>isabelcpchsm@santamarcelina.org</email>
    </contact>
    <investigator>
      <last_name>Paulo Guilherme O Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São Camilo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Gonçalves</last_name>
      <phone>55 11 3677-4444</phone>
      <phone_ext>5015</phone_ext>
      <email>pesquisa.iep@saocamilo.com</email>
    </contact>
    <investigator>
      <last_name>Humberto Freitas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMA - Instituto de Medicina Avançada</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Fakih</last_name>
      <phone>55 11 38639156</phone>
      <email>daniela.fakih@imabrasil.com.br</email>
    </contact>
    <investigator>
      <last_name>Marise L Castro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chlortalidone</keyword>
  <keyword>amiloride</keyword>
  <keyword>arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

